In this issue:
- Ustekinumab vs adalimumab for moderately-to-severely active CD
- IBD nutrition self-screening tool
- Ustekinumab or vedolizumab for CD refractory to anti-TNF
- Ustekinumab for perianal fistulising CD
- Obesity and risk of hospitalisation, surgery and serious infections with biologics
- Immunomodulator comedication for anti-drug antibody-mediated anti-TNF LOR
- Food additives, bacterial taxa and mucosa-associated microbiota in CD
- Predictors of IBD disease activity during pregnancy
- Risk factors for developing IBD within and across families
- Risk of MAFLD and liver fibrosis in IBD
- Science blog: Alcohol and IBD Blues
Please login below to download this issue (PDF)